Skip to main content
Figure 4 | Molecular Medicine

Figure 4

From: The Interleukin-8 (IL-8/CXCL8) Receptor Inhibitor Reparixin Improves Neurological Deficits and Reduces Long-term Inflammation in Permanent and Transient Cerebral Ischemia in Rats

Figure 4

Effect of reparixin treatment under different schedules on neurological deficits after transient MCAO. Transient (1.5 h) MCAO was performed. Reparixin was administered as follows: Panels A–C: 15 mg/kg, i.v. 2 h after reperfusion (i.e. 3.5 h after MCAO) followed by two 15 mg/kg s.c. doses at 2 h intervals, then 3 times/day on days 2 and 3. Panels D–F: 15 mg/kg, i.v. 2 h after reperfusion (i.e. 3.5 h after MCAO) followed by s.c. infusion for 48 h at a rate of 10mg/h/kg. Panels G–I: 15 mg/kg, i.v. 4.5 h after reperfusion (6 h after MCAO) followed by s.c. infusion for 48 h at a rate of 10mg/h/kg. Neurological deficits were evaluated by De Ryck’s (left panels), Bederson’s (middle panels) and foot-fault (right panels) tests starting from 24 h after MCAO. Open circles, vehicle; closed circles, reparixin. For comparison, the scores of non-ischemic, sham-operated rats, i.e. “normal” values, are also shown as a thin line (normal values were: 16 for the De Ryck’s test, 5 for the Bederson’s test and 1–4 for the foot-fault test. Data are mean ± S.E. of 6–7. Statistical differences (Mann-Whitney): *P < 0.05 and **P < 0.01 vs. saline.

Back to article page